John L. Villano

10.3k citations

141 papers · 5.0k indexed · 3 hit papers · h-index 34

Genetics top 0.2%
- Glioma Diagnosis and Treatment 71
Neurology top 1%
Cancer Research top 5%
- Cancer Genomics and Diagnostics 14
Pulmonary and Respiratory Medicine top 2%
- Brain Metastases and Treatment 36
- Lung Cancer Treatments and Mutations 15
Oncology top 5%
- Lung Cancer Research Studies 11
- Cancer Treatment and Pharmacology 10
Epidemiology
- Meningioma and schwannoma management 16
Radiology, Nuclear Medicine and Imaging
- Radiomics and Machine Learning in Medical Imaging 10

Co-authors: Therese A. Dolecek Bridget J. McCarthy Jigisha P. Thakkar Donita Lightner Craig Horbinski Quinn T. Ostrom Jill S. Barnholtz‐Sloan Matthew Koshy
Cited by: Genetics Neurology Cancer Research
Partner nations: United States Canada Spain

In The Last Decade

John L. Villano

136 papers receiving 4.9k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
2014 Epidemiologic and Molecular Prognostic Review of Glioblastoma
2011 Age, gender, and racial differences in incidence and survival in primary CNS lymphoma

Peers

Countries citing papers authored by John L. Villano

Since Specialization

Citations

This map shows the geographic impact of John L. Villano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Villano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Villano more than expected).

Fields of papers citing papers by John L. Villano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Villano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Villano. The network helps show where John L. Villano may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John L. Villano, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John L. Villano Line = papers co-authored together John L. Villano links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity Morgan E Cantley,C. Norman Coleman,Rachael Morgan,Niharika Reddy,Sarah Sertich,John L. Villano	2025	0
2	Outcomes of Brain Metastasis from Lung Cancer James M. Mobley,Kathryn A. Phillips,Quan Chen,Ellen Reusch,Niharika Reddy,Julia Magsam,Laurie E. McLouth,Bin Huang,John L. Villano	2025	2
3	Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study Megan L. Hutchcraft,Shulin Zhang,Nan Lin,Justine Pickarski,E Belcher,Sainan Wei,Thèrése Bocklage,Rachel W. Miller,John L. Villano,Michael J. Cavnar,Joseph Kim,Susanne M. Arnold,Frederick R. Ueland,Jill Kolesar	2024	1
4	A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas Olivier Rixe,John L. Villano,Robert Wesolowski,Anne M. Noonan,Vinay K. Puduvalli,Trisha M. Wise‐Draper,Richard Curry,Emrullah Yilmaz,Charlie Cruze,Besim Öğretmen,Gilles Tapolsky,Ray Takigiku	2024	1
5	Profiling the molecular and clinical landscape of glioblastoma utilizing the Oncology Research Information Exchange Network brain cancer database Alexandra N. Demetriou,Frances Chow,David W. Craig,Michelle G. Webb,D. Ryan Ormond,James Battiste,Arnab Chakravarti,Howard Colman,John L. Villano,Bryan P. Schneider,James K. Liu,Michelle L. Churchman,Gabriel Zada	2024	3
6	Case report: A unique presentation of a high-grade neuroepithelial tumor with EWSR1::PATZ1 fusion with diagnostic, molecular, and therapeutic insights Andre Ene,Jing Di,Janna H. Neltner,Thomas Pittman,Susanne M. Arnold,Jill Kolesar,John L. Villano,S. Emily Bachert,Derek B. Allison	2023	5
7	Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial Rachel W. Miller,Megan L. Hutchcraft,Heidi L. Weiss,Jianrong Wu,Chi Wang,Jinpeng Liu,Rani Jayswal,Mikayla Buchanan,Abigail Anderson,Derek B. Allison,Riham El Khouli,Reema Patel,John L. Villano,Susanne M. Arnold,Jill Kolesar	2022	21
8	NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastomabreakdown → Christina Tsien,Stephanie L. Pugh,Adam P. Dicker,Jeffrey J. Raizer,M.M. Matuszak,Enrico C. Lallana,Jiayi Huang,Özer Algan,Nimisha Deb,Lorraine Portelance,John L. Villano,John Hamm,Kevin Oh,Arif N. Ali,Michelle M. Kim,Scott Lindhorst,Minesh P. Mehta	2022	104
9	Molecular Tumor Board Review and Improved Overall Survival in Non–Small-Cell Lung Cancer Bin Huang,Quan Chen,Derek B. Allison,Riham El Khouli,Keng Hee Peh,James A. Mobley,Abigail Anderson,Eric B. Durbin,Donald Goodin,John L. Villano,Rachel W. Miller,Susanne M. Arnold,Jill Kolesar	2021	18
10	Not So Benign: A Rare Atypical Ectopic Choroid Plexus Papilloma Rajan Patel,Douglas Lukins,John L. Villano,Pushpalatha Sudhakar	2021	0
11	Comprehensive Review of Cranial Chordomas Using National Databases in the USA M. Maher Hulou,Catherine R. García,Stacey Slone,Adam Dugan,Feitong Lei,Bin Huang,Thomas Pittman,John L. Villano	2019	16
12	Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas Catherine R. García,Stacey Slone,Thomas Pittman,William H. St. Clair,Donita Lightner,John L. Villano	2018	18
13	Multimodality therapy improves survival in intramedullary spinal cord metastasis of lung primary Hayder Saeed,Reema Patel,Jigisha P. Thakkar,Lames Hamoodi,Li Chen,John L. Villano	2017	11
14	Narrative Medicine perspectives on patient identity and integrative care in neuro-oncology Robert B. Slocum,Tracy A. Howard,John L. Villano	2017	10
15	Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study Kimberly R. Porter,Usha Menon,Nicholas A. Vick,John L. Villano,Michael L. Berbaum,Faith G. Davis	2014	9
16	Descriptive epidemiology of ependymal tumours in the United States John L. Villano,C K Parker,Therese A. Dolecek	2013	47
17	Long-term survival in an untreated patient with leptomeningeal carcinomatosis from breast primary Simran Singh,Vibhav Bansal,Elizabeth L. Wiley,Tibor Vályi-Nagy,John L. Villano	2012	8
18	Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases Oana C. Danciu,Shayan Rayani,Edward A. Michals,John L. Villano	2011	3
19	Going past the data for temozolomide John L. Villano,Nathalie Letarte,Linda R. Bressler	2011	3
20	Malignant pineal germ-cell tumors: An analysis of cases from three tumor registries John L. Villano,Jennifer M. Propp,Kimberly R. Porter,Andrew K. Stewart,Tibor Vályi-Nagy,Xinyu Li,Herbert H. Engelhard,Bridget J. McCarthy	2008	89

About John L. Villano

John L. Villano is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology, having authored 141 papers that have together received 5.0k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (71 papers), Brain Metastases and Treatment (36 papers), Meningioma and schwannoma management (16 papers), Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (14 papers), Lung Cancer Research Studies (11 papers), Radiomics and Machine Learning in Medical Imaging (10 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Genetics (2.6k citations), Neurology (1.1k citations) and Cancer Research (623 citations). John L. Villano has collaborated with scholars based in United States, Canada and Spain. Frequent co-authors include Therese A. Dolecek, Bridget J. McCarthy, Jigisha P. Thakkar, Donita Lightner, Craig Horbinski, Quinn T. Ostrom, Jill S. Barnholtz‐Sloan, Matthew Koshy, Linda R. Bressler and Habib Shaikh.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact